SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (159)11/14/1997 12:43:00 AM
From: Druss  Respond to of 1510
 
MJ--Here is a paragraph from a company press release of Sept 22.
The Immune Response Corporation has numerous clinical trials of REMUNE underway including a Phase III clinical endpoint study involving 2,500 patients; a Phase II combination drug trial being conducted in conjunction with Glaxo Wellcome, plc and Merck & Co., additional Phase II trials in Thailand and Spain; and a Phase I trial in children at the National Institutes of Health.
Hope this helps.
All the Best
Druss



To: MJ who wrote (159)11/15/1997 7:01:00 PM
From: Robert DeHaven  Read Replies (1) | Respond to of 1510
 
IMNR has entered Phase III with Remune...I expect results within 6 months....

Also I would expect some corporate partnerships to develop as Phase III and ultimately FDA approval come closer. I have read an analyst report which also supports this thought and expect announcements during Q4

Good luck,

Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News